1. BusinessWire.com: Virios Therapeutics highlights clinical sites fully operational in phase 2b fibromyalgia study featuring FDA “fast track” review designated antiviral therapy, oral IMC-1 From the article: "Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on

1. NeuroMetrix.com: NeuroMetrix receives FDA breakthrough device designation for treatment of fibromyalgia with its wearable neurostimulation technology From the article: "A total of 119 subjects with fibromyalgia were enrolled and randomized to a standard (active) or modified (sham) Quell

1. Pain News Network: Revised CDC opioid guideline not expected until late 2022 From the article: “CDC anticipates that the draft updated guideline will be posted for public comment by the end of 2021. This will provide another critical opportunity for diverse input from the public,” Lenard

1. King's College London: New study shows fibromyalgia likely the result of autoimmune problems This has been big news within the fibromyalgia community on Facebook. I'm always hesitant to get excited about mouse studies, but it does sound promising. From the press release: "The

1. Psychedelic News Wire: Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) presentation to provide overview of psychedelic drug candidate program at Ladenburg Thalmann Healthcare Conference From the article: "Tryp is developing its lead drug candidate, TRP-8802, as a potentially novel drug

1. Axsome Therapeutics: Axsome Therapeutics announces planned NDA submission for AXS-14 for the management of fibromyalgia From the press release: "In the phase 3 trial, 1,122 patients with fibromyalgia were treated with AXS-14 (esreboxetine) or placebo for 14 weeks. The study met the